AOD-9604 vs Retatrutide: What the Research Shows
AOD-9604 and Retatrutide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider AOD-9604 if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
Consider Retatrutide if…
- you are weighing an investigational option (no FDA-approved product yet): the TRIUMPH trial reported mean weight change of -25.0% with the 12-mg dose versus -3.9% with placebo[1]
- you want to know where approval stands: Lilly states it plans to submit a Biologics License Application to the FDA, a submission plan and not an approval[15]
What they have in common
- Only animal or lab studies of AOD-9604 were found (e.g. rat): Oral AOD9604 for 19 days cut body weight gain by over 50% (15.8 g vs 35.6 g control) in obese Zucker rats.[8]
Spec comparison
Showing 11 of 13 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.
| Field | AOD-9604 | Retatrutide |
|---|---|---|
| Class | HGH fragment analog | GLP-1 / GIP / glucagon triple agonist |
| Also called | AOD | reta, GLP-3, LY3437943 |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | Investigational · phase 3 |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times. | Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040 |
| Evidence strength | Animal evidence, 2 of 4Strongest: Annals of clinical and laboratory science 2015, PMID 26275694 | Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 4 summarised | 11 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg | 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
AOD-9604 and Retatrutide together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Animal fat-metabolism data versus completed phase 3 trials
AOD-9604's weight evidence here comes from obese mice, where AOD9604 and growth hormone both reduced body weight and body fat after 14 days of chronic intraperitoneal dosing.[16]
In retatrutide's phase 2 trial, mean weight loss at 48 weeks rose with each dose group and exceeded the placebo group's in all of them.[17]
The phase 3 TRIUMPH-1 trial randomised 2339 participants. Its primary outcomes were assessed in subgroups with knee osteoarthritis and with obstructive sleep apnea.[1]
In TRIUMPH-1, the most common adverse events with retatrutide were gastrointestinal. No human trial results for AOD-9604 are cited here to compare.[1]
Mechanism and regulatory status
Retatrutide is a single peptide with agonist activity at the glucagon, GIP and GLP-1 receptors. AOD9604 was designed as the lipolytic domain of growth hormone, so the mechanisms are unrelated.[10]
The Drugs@FDA search for retatrutide returned no matches.[18]
The Drugs@FDA search for AOD-9604 also returned no matches.[19]
Common questions
AOD-9604 vs retatrutide: which works better?
In the cited abstracts, only retatrutide has randomised human weight data. AOD-9604's weight results are from animals.[17]
Is AOD-9604 like a mini retatrutide?
No. Retatrutide acts on the glucagon, GIP and GLP-1 receptors, while AOD-9604 is a growth hormone fragment studied for lipolysis in animals.[10]
Can I get either on prescription?
Neither appears in Drugs@FDA as an approved product; both searches returned no matches.[19]
Sources
- 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 6Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
- 7Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
- 8Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
- 9PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 11Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 12Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 13PubMed search: ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 15Official web pageOfficial web page · web page
- 16The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.Endocrinology · 2001PMID 11713213Accessed 2 Oct 2026
- 17Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 18Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 19Drugs@FDA (openFDA) search: active ingredient "AOD-9604"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.